Fight against COVID-19
Diagnostic antibody & antigen
Services
- Custom AAV Production
- Custom Adenovirus Production
- Custom Lentivirus Production
- Pre-made AAV Production
- Pre-made Adenovirus Production
- Pre-made Lentivirus Production
- AAV-LC3 Autophagy Flux Detection
- Ad-LC3 Autophagy Flux Detection
- Lv-LC3 Autophagy Flux Detection
- AAV Control Virus Production
- CRISPR/Cas9 AAV Production
- CRISPR/Cas9 Adenovirus Production
Supports
SOCAIL MEDIA
AAV6 Rep-Cap plasmid (serotype 6-specific AAV RC6 plasmids)
AAV protocol Download
AAV User Manual Download
AAV serotype 6 (AAV capsid 6) system - Introduction
GeneMedi's AAV6 Rep-Cap plasmid (serotype 6-specific AAV RC plasmid), also named AAV6-RC plasmid, or AAV-RC6 plasmid, is part of AAV6 packaging system. AAV6 Rep-Cap plamid supplies the AAV6 Rep (replication) proteins and the AAV6 capsid protein.
You can produce AAV6 paticle in 293T cell line in high titer using GeneMedi's AAV6 Rep-Cap plasmid with GeneMedi's AAV expression vector (overexpression or shRNA) and AAV helper plasmid.
The tissue tropism of AAV6 vector has been validated in neuron (CNS), lung, liver, heart and muscle, with potential applications in tissue-specific gene therapy.
AAV6 has also been proved a high transduction efficency in T cell, wtih potential applications in T cell-mediated cancer immunotherapies, including Chimaeric antigen receptor T(CAR-T) and TCR engineered T (TCR-T) cell therapy.
| Product Name | Contents | Price(In USD) | Qty (Quantity) | Sum(In USD) |
|---|---|---|---|---|
| AAV6 Rep-Cap Plasmid | Serotype: AAV6 Size: 5ug |
590 | ||
| Shipping Cost: | 360.00 | |||
| Total: | ||||
AAV6 vector tissue tropism and gene transduction (serotype-specific AAV infection)
The tissue tropism of AAV6 vector has been validated in neuron (CNS), lung, liver, heart and muscle, with potential applications in tissue-specific gene therapy.
AAV6 has also been proved a high transduction efficency in T cell, wtih potential applications in T cell-mediated cancer immunotherapies, including Chimaeric antigen receptor T(CAR-T) and TCR engineered T (TCR-T) cell therapy.
Virus and titer: AAV1/AAV6/AAV8/AAV-Rh10/AAV-DJ/AAV9-GFP, 1×1012 vg/ml Cells: HEK-293T MOI: MOI=1×104 Determine assay: 36 hours post infection, immunofluorescence microscopy
Other AAV Rep-Cap Plasmid
